Cargando…
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Inhibitory properties of PD-1 receptor engagement on activated T cells are well established in physiologic and pathological contexts. In cancer, the use of checkpoint blockade, such as anti-PD-1 antibodies, becomes progressively a reference treatment of a growing number of tumors. Nonetheless, it is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739549/ https://www.ncbi.nlm.nih.gov/pubmed/29296515 http://dx.doi.org/10.1080/2162402X.2017.1364828 |